Log in to search using one of your social media accounts:

 

Breast Implants Linked to Anaplastic Large-Cell Lymphoma
In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 24, 2017 Category: Cancer & Oncology Authors: Francisco Hernandez-Ilizaliturri, MD Scott Chapin, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Q T-Cell Lymphomas Source Type: news

BioCryst to receive royalties from cancer treatment approved in Japan
Durham-based BioCryst Pharmaceuticals (Nasdaq: BCRX) stands to receive royalties from a new cancer therapy approved in Japan. The company announced that Mundipharma – with which it has a sub-licensing agreement – has received approval from the the Ministry of Health, Labor and Welfare in Japan for Mundesine, a therapy for the treatment of Peripheral T-Cell Lymphoma. “Under the terms of the agreement with Mundiphar ma, BioCryst will receive tiered royalties ranging from the mid- to high-single… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 4, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

Mundipharma ’s Mundesine receives approval from Japan’s MHLW to treat PTCL
Mundipharma has secured regulatory approval of Mundesine (Forodesine hydrochloride) from Japan ’s Ministry of Health, Labour and Welfare (MHLW) to treat relapsed / refractory Peripheral T-Cell Lymphoma (PTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 3, 2017 Category: Pharmaceuticals Source Type: news

BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
RESEARCH TRIANGLE PARK, N.C., April 03, 2017 -- (Healthcare Sales & Marketing Network) -- BioCryst Pharmaceuticals, Inc. (BCRX) announced today that Mundipharma has obtained regulatory approval of Mundesine® (Forodesine hydrochloride) for the treatment... Biopharmaceuticals, Oncology, Regulatory BioCryst Pharmaceuticals, Mundesine, Forodesine, Peripheral T-Cell Lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2017 Category: Pharmaceuticals Source Type: news

FDA Warns of Rare Cancer Linked to Breast Implants
The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery. (Source: CancerNetwork)
Source: CancerNetwork - March 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Leukemia & Lymphoma News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for March 22, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Japan clears Novocure’s 2nd gen Optune device Novocure said today it won approval from the Japanese Ministry of Health, Labour and Welfare for its 2nd-gen Optune device. The Optune is a mobile device that delivers low-int...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: MassDevice Tags: Blog News Well Plus 5 Source Type: news

FDA warns on lymphoma risk associated with breast implants
The FDA this month warned of an association between breast implants and the development anapestic large cell lymphoma. The federal watchdog warned that the rare T-cell lymphoma can develop following implants, based on data the agency, and other health and regulatory bodies worldwide, have been collecting since 2011. The exact number of cases “remains difficult to determine,” the FDA said, though data indicates that the occurrence of BIA-ALCL is more common following the implantation of breast implants with textured surfaces over those with smooth surfaces. The FDA said it has received a total of 359 medical dev...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cosmetic/Aesthetic Food & Drug Administration (FDA) Women's Health Source Type: news

FDA Update on Rare Breast Implant-Associated Type of Lymphoma FDA Update on Rare Breast Implant-Associated Type of Lymphoma
The FDA says breast implant-associated anaplastic large cell lymphoma is a rare T cell lymphoma that can develop after breast implants and provides guidance for clinicians.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 21, 2017 Category: Cancer & Oncology Tags: Plastic Surgery & Aesthetic Medicine News Alert Source Type: news

EC grants marketing authorisation for Actelion ’s Ledaga to treat MF-CTCL
The European Commission (EC) has granted marketing authorisation for 160mcg of Actelion ’s Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news

New Therapies for T-Cell Lymphomas on the Horizon
There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/ICHM 2017 Leukemia & Lymphoma Source Type: news

Cancer Case Against Monsanto For Glyphosate Exposure Sent To Roundup MDL
WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation on Feb. 15 transferred to the multidistrict litigation in the U.S. District Court for the Northern District of California the case of a man who contends that his exposure to glyphosate, the active ingredient in the herbicide Roundup, caused him to develop NK/T-cell lymphoma (In Re: Roundup Products Liability Litigation, No. 2741, JPMDL). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - February 21, 2017 Category: Medical Law Source Type: news

Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma
Brentuximab vedotin showed clinically superior outcomes compared with standard of care in patients with cutaneous T cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

High-Dose RT Improved Survival in Aggressive Lymphoma
The use of radiotherapy may have an important role in optimizing first-line treatment for patients with early-stage extranodal natural killer/T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 24, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Seattle Genetics and Takeda Pharmaceutical complete enrolment for Phase III ECHELON-2 trial of ADCETRIS
Seattle Genetics and Takeda Pharmaceutical have completed patient enrolment for the Phase III ECHELON-2 clinical trial of ADCETRIS (brentuximab vedotin) to treat CD30-positive mature T-cell lymphoma (MTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - November 10, 2016 Category: Pharmaceuticals Source Type: news

Supportive Care for T-Cell Lymphomas
In this interview we discuss the different types of T-cell lymphomas and how supportive care is used in the management of these malignancies. (Source: CancerNetwork)
Source: CancerNetwork - October 1, 2016 Category: Cancer & Oncology Authors: Erin Kopp, ACNP-BC Tags: Hematologic Malignancies Leukemia & Lymphoma Conferences/NCCN 2016 Palliative and Supportive Care Source Type: news

Angimmune ’s Investigational Cutaneous T-cell Lymphoma Disease...
FDA Fast Track Granted to Angimmune(PRWeb September 13, 2016)Read the full story at http://www.prweb.com/releases/angimmune/201609/prweb13679453.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 13, 2016 Category: Pharmaceuticals Source Type: news

Takeda and Seattle Genetics report positive results from Phase III ALCANZA trial of Adcetris to treat CTCL
Takeda Pharmaceutical and Seattle Genetics have reported positive results from the Phase III ALCANZA clinical trial of Adcetris to treat cutaneous T-cell lymphoma (CTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2016 Category: Pharmaceuticals Source Type: news

Severe psoriasis upped lymphoma risk in large cohort study
SCOTTSDALE, ARIZ. – Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5 times, in a large, longitudinal, population-based cohort study. Psoriasis also was tied to a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 6, 2016 Category: Dermatology Source Type: news

Severe psoriasis upped lymphoma risk in large cohort study
SCOTTSDALE, ARIZ. – Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5... (Source: Family Practice News)
Source: Family Practice News - July 6, 2016 Category: Primary Care Source Type: news

PharmaMar begins pivotal study of plitidepsin to treat angioimmunoblastic T-cell lymphoma
Spanish-based biopharmaceutical company PharmaMar has commenced the multicentre, prospective, pivotal study to assess the efficacy of anti-cancer agent plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - June 15, 2016 Category: Pharmaceuticals Source Type: news

PharmaMar announces the start of a pivotal study with plitidepsin in T-cell lymphoma
(Pharmamar) The primary endpoint is to analyze the efficacy of plitidepsin in the type of hematological cancer, angioimmunoblastic T-cell lymphoma, which is classified as a rare disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2016 Category: Cancer & Oncology Source Type: news

Cutaneous T-Cell Lymphoma: Focus on Targeted AgentsCutaneous T-Cell Lymphoma: Focus on Targeted Agents
This review explores the latest targeted therapies which provide treatment options for patients with advanced cutaneous T-cell lymphoma. Which are currently approved and which are under investigation? American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2016 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma
Patients with cutaneous T-cell lymphoma who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news

Dose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell LymphomaDose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell Lymphoma
Romidepsin regimens that employ less-frequent dosing can prolong remission in patients with some subtypes of cutaneous T-cell lymphoma (CTCL), according to a retrospective records review. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

APO866 lacks efficacy in cutaneous T-cell lymphoma
The nicotinamide adenine dinucleotide biosynthesis inhibitor APO866 does not show efficacy in patients with cutaneous T-cell lymphoma, according to phase II trial results reported in JAMA Dermatology. (Source: MedWire News)
Source: MedWire News - April 7, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news

Japan's Solasia begins Phase II trial of lymphoma drug darinaparsin
Japan-based Solasia Pharma has started an Asian Multinational Phase II trial of SP-02 (darinaparsin) for injection (SP-02L) to treat relapsed and refractory peripheral T-cell lymphoma (PTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - March 28, 2016 Category: Pharmaceuticals Source Type: news

miRagen begins Phase I trial for MRG-106 to treat cutaneous T-cell lymphoma
US-based miRagen Therapeutics has started a Phase I trial of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, to treat patients with lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 3, 2016 Category: Pharmaceuticals Source Type: news

Lenalidomide trials show potential for expanding lymphoma, leukaemia indications
Positive findings from two clinical trials have been published for the immunomodulatory agent lenalidomide in patients with heavily pretreated mantle cell lymphoma, and in adults with T-cell leukaemia–lymphoma or peripheral T-cell lymphoma. (Source: MedWire News)
Source: MedWire News - February 21, 2016 Category: Consumer Health News Tags: Leukaemia Source Type: news

Primary CNS T-Cell Lymphoma of the Spinal CordPrimary CNS T-Cell Lymphoma of the Spinal Cord
The rare cause of this 82-year-old man's progressive lower back pain and lower extremity weakness was only confirmed after death. Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 19, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Topical resiquimod effective for early-stage cutaneous T-cell lymphoma
Topical resiquimod was effective and well tolerated in patients with early-stage cutaneous T-cell lymphoma (CTCL), in some cases inducing regression in both treated and untreated lesions, according to researchers. The mean number of prior unsuccessful therapies among the patients was 6, yet the... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 24, 2015 Category: Dermatology Source Type: news

Medical News Today: Topical drug leads to complete remission for some patients with rare skin lymphoma
Researchers reveal how a topical drug called resiquimod led to total remission for some patients with a cutaneous T cell lymphoma - a rare skin lymphoma. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 7, 2015 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Topical gel proves safe, effective treatment for patients with skin t cell lymphoma
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma that affects the skin. Currently, there is no cure for CTCL aside from a bone marrow transplant. However, the new study shows that the topical gel can eliminate malignant T cells, leading to diminished lesions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 6, 2015 Category: Science Source Type: news

Naloxone lotion improves disabling itch in CTCL
VANCOUVER, B.C. – Naloxone lotion appears to be a safe and effective treatment for the severe chronic itching that occurs in most patients with cutaneous T-cell lymphoma, Dr. Madeleine Duvic reported at the World Congress of Dermatology. A major unmet need exists for better treatments for...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 2, 2015 Category: Dermatology Source Type: news

Your NEJM Group Today: Cutaneous T-Cell Lymphoma, Sunscreen Use, Washington State IM Opportunity (FREE)
By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 23, 2015 Category: Primary Care Source Type: news

Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market...
RnRMarketResearch.com adds “Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015” to its store. The report provides an overview of the Cutaneous T-Cell Lymphoma’s therapeutic pipeline.(PRWeb April 07, 2015)Read the full story at http://www.prweb.com/releases/cutaneous-t-cell-lymphoma/pipeline-review-h1-2015/prweb12636381.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 7, 2015 Category: Pharmaceuticals Source Type: news

Takeda announces 4-year survival data from ADCETRIS® pivotal trial at ASH annual meeting
Takeda UK announced 4-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 10, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Other conferences & symposia Oncology Patient care ALCL antibody-drug conjugate brentuximab vedotin Hodgkin lymphoma Latest News Source Type: news

Agios begins Phase I/II trial of AG-221 to treat advanced solid tumours
Agios Pharmaceuticals has started a Phase I/II multicentre trial of AG-221 in patients with advanced solid tumours, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation. (Source: Drug Development Technology)
Source: Drug Development Technology - October 21, 2014 Category: Pharmaceuticals Source Type: news

Beleodaq (Belinostat) for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 10, 2014 Category: Pharmaceuticals Source Type: news

What is the Cause? Erythematous Rash
(MedPage Today) -- An elderly patient with known T-cell lymphoma and splenomegaly develops a well demarcated erythematous lesion on her upper arm. A biopsy of the lesion demonstrates a neutrophilic infiltrate. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - August 5, 2014 Category: Dermatology Source Type: news

New Drug Approved for Peripheral T-Cell Lymphoma (FREE)
By the Editors The FDA has approved … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 7, 2014 Category: Primary Care Source Type: news

Beleodaq OK'd for Rare Form of NHL
WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL). (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 3, 2014 Category: Hematology Source Type: news

FDA Approves Belinostat for Rare LymphomaFDA Approves Belinostat for Rare Lymphoma
The new drug is for peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin's lymphoma. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 3, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 3, 2014 Category: American Health Source Type: news

Response to Alemtuzumab for Leukemic Cutaneous T-Cell LymphomaResponse to Alemtuzumab for Leukemic Cutaneous T-Cell Lymphoma
Patients with leukemic cutaneous T-cell lymphoma (CTCL) who have diffuse erythema are more likely to experience complete response to alemtuzumab therapy, according to results from a small series. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 2, 2014 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Donor Lymphocyte Infusion Improves Survival in Relapsed LymphomaDonor Lymphocyte Infusion Improves Survival in Relapsed Lymphoma
Relapsed patients with peripheral T cell lymphoma after transplant show improved survival when treated with a donor lymphocyte infusion. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 9, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novel Drug Shows Promise in T-Cell Lymphoma
DENVER (MedPage Today) -- An investigational drug, resiquimod, successfully healed cutaneous T-cell lymphoma lesions in a small peer-supported trial, researchers reported here. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 24, 2014 Category: Dermatology Source Type: news

Belinostat (PXD 101) for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Belinostat (PXD 101) is a histone deacetylase (HDAC) inhibitor that is being investigated for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - January 31, 2014 Category: Pharmaceuticals Source Type: news

Infinity reports positive Phase I results of lymphoma drug IPI-145
Infinity Pharmaceuticals has reported promising data from an ongoing Phase I trial of its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma 'IPI-145' in patients with relapsed/refractory T-cell lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - January 28, 2014 Category: Pharmaceuticals Source Type: news

Peripheral T-Cell Lymphoma: What’s the Role for Transplant?
The number of recently approved agents and those under investigation is promising. However, there are currently no recommendations regarding the optimal timing for use of these agents, a reflection of the lack of data in this area and the need for prospective studies. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news